Member Directory
Member Directory

Drug Manufacturer GSK Reaches a $1.2 Billion Patent Settlement

Drug giant GlaxoSmithKline earned two victories in the ongoing battle to treat AIDS, one involving a patent settlement and the other securing FDA approval for a longer-term HIV treatment from GSK-owned ViiV Healthcare.

First, the patent.

GSK (NYSE: GSK) disclosed Tuesday it had reached a patent settlement with rival Gilead in a dispute over technology used in an HIV drug. ViiV, GSK and ViiV part-owner Shionogi had charged Gilead’s HIV drug Biktarvy infringed ViiV patents.

Gilead agreed to pay a one-time fee of $1.25 billion in the first quarter of this year plus 3% royalties. The money will be divided among ViiV’s owners, which includes Pfizer.

Read the source article at WRAL TechWire

Find an Attorney

The National Trial Lawyers stands as an esteemed, exclusive association comprising top-tier trial attorneys nationwide. Whether you require a Civil Plaintiff Lawyer or a Criminal Defense Lawyer in your state, our network ensures access to premier legal expertise tailored to your needs.
Find Attorney

Read More Legal News

© Copyright 2022, All Rights Reserved | National Trial Lawyers
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram